Cargando…

Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin

Therapeutic protocols including EGFR antibodies in the context of oxaliplatin-based regimens have variable clinical effect in colorectal cancer. Here, we tested the effect of the EGFR antibody cetuximab in different sequential combinations with oxaliplatin on the growth of colorectal cancer cells in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Narvi, Elli, Vaparanta, Katri, Karrila, Anna, Chakroborty, Deepankar, Knuutila, Sakari, Pulliainen, Arto, Sundvall, Maria, Elenius, Klaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224565/ https://www.ncbi.nlm.nih.gov/pubmed/30410004 http://dx.doi.org/10.1038/s41598-018-34938-y

Ejemplares similares

Combined genetic and chemical screens indicate protective potential for EGFR inhibition to cardiomyocytes under hypoxia
por: Heliste, Juho, et al.
Publicado: (2021)

Exotoxin-Targeted Drug Modalities as Antibiotic Alternatives
por: Sakari, Moona, et al.
Publicado: (2022)

Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target
por: Heliste, Juho, et al.
Publicado: (2018)

Systemic Analysis of Gene Expression Profiles Identifies ErbB3 as a Potential Drug Target in Pediatric Alveolar Rhabdomyosarcoma
por: Nordberg, Janne, et al.
Publicado: (2012)

Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer
por: Santoro, Valeria, et al.
Publicado: (2015)

Genome-wide screen of gamma-secretase–mediated intramembrane cleavage of receptor tyrosine kinases
por: Merilahti, Johannes A. M., et al.
Publicado: (2017)

An extracellular receptor tyrosine kinase motif orchestrating intracellular STAT activation
por: Vaparanta, Katri, et al.
Publicado: (2022)

Gene mutations in stool from gastric and colorectal neoplasia patients by next-generation sequencing
por: Youssef, Omar, et al.
Publicado: (2017)

Cell Death or Survival Promoted by Alternative Isoforms of ErbB4
por: Sundvall, Maria, et al.
Publicado: (2010)

A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
por: Koo, Dong Hoe, et al.
Publicado: (2007)

Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer
por: Hashimoto, Akari, et al.
Publicado: (2014)

Gemcitabine: An Alternative Treatment for Oxaliplatin-Resistant Colorectal Cancer
por: Chocry, Mathieu, et al.
Publicado: (2022)

Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial
por: Garufi, C, et al.
Publicado: (2010)

Endothelial Cells Regulate Physiological Cardiomyocyte Growth via VEGFR2-Mediated Paracrine Signaling
por: Kivelä, Riikka, et al.
Publicado: (2019)

Biomarker analysis in human neoplasias: superior next-generation sequencing on frozen bone marrow cells and on formalin-fixed, paraffin-embedded tumor tissues
por: Knuutila, Sakari
Publicado: (2013)

Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer
por: Wei, Li, et al.
Publicado: (2020)

Hepatic arterial infusion but not systemic application of cetuximab in combination with oxaliplatin significantly reduces growth of CC531 colorectal rat liver metastases
por: Sperling, Jens, et al.
Publicado: (2012)

Cetuximab in the management of colorectal cancer
por: Lenz, Heinz-Josef
Publicado: (2007)

Crystal structures of pertussis toxin with NAD(+) and analogs provide structural insights into the mechanism of its cytosolic ADP-ribosylation activity
por: Sakari, Moona, et al.
Publicado: (2022)

Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation
por: Balin-Gauthier, D, et al.
Publicado: (2008)

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience
por: Adams, R A, et al.
Publicado: (2009)

Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer
por: Zhang, Zhan-Dong, et al.
Publicado: (2014)

UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Petrioli, R, et al.
Publicado: (2004)

UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Alliot, C
Publicado: (2004)

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
por: Maughan, Timothy S, et al.
Publicado: (2011)

Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer
por: Pander, Jan, et al.
Publicado: (2015)

Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
por: Folprecht, Gunnar, et al.
Publicado: (2014)

Reply: UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Francini, G, et al.
Publicado: (2004)

Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer
por: Sheikh, H Y, et al.
Publicado: (2008)

An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations
por: Chakroborty, Deepankar, et al.
Publicado: (2022)

Right- and left-sided colorectal cancers respond differently to cetuximab
por: Wang, Feng, et al.
Publicado: (2015)

Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study
por: Tarpgaard, Line S., et al.
Publicado: (2014)

Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with RAS wild-type metastatic colorectal cancer
por: Zekri, Jamal, et al.
Publicado: (2022)

Therapeutic Potential of Targeting the SUMO Pathway in Cancer
por: Kukkula, Antti, et al.
Publicado: (2021)

Evolving role of cetuximab in the treatment of colorectal cancer
por: Schuch, Gunter, et al.
Publicado: (2009)

PRSS contributes to cetuximab resistance in colorectal cancer
por: Tan, Zhaoli, et al.
Publicado: (2020)

Gut microbiota of patients with different subtypes of gastric cancer and gastrointestinal stromal tumors
por: Sarhadi, Virinder, et al.
Publicado: (2021)

Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy
por: Sperling, Jens, et al.
Publicado: (2012)

Correction: Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study
Publicado: (2014)

Association between polymorphisms in EGFR and tumor response during cetuximab and oxaliplatin-based combination therapy in metastatic colorectal cancer: Analysis of data from two clinical trials
por: Maeda, Hiromichi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v5tet1lfpieoviqmqaoif5cvfa